Literature DB >> 10828631

Minocycline-induced lupus. A systematic review.

R G Schlienger1, A J Bircher, C R Meier.   

Abstract

BACKGROUND: Minocycline has increasingly been associated with different adverse auto-immune reactions including drug-induced lupus.
OBJECTIVE: To identify the scope of minocycline-induced lupus and to characterise its typical features.
METHODS: Comprehensive Medline and Embase search of the English and non-English literature for case reports of minocycline-induced lupus.
RESULTS: We included 57 cases of minocycline-induced lupus (mean age +/- SD at onset: 21.6+/-8.6 years, median time of exposure: 19 months, range 3 days to 6 years). All patients showed the clinical features of polyarthralgia/polyarthritis often accompanied by liver abnormalities. Twelve patients had evidence of dermatological manifestations (i.e rash, livedo reticularis, oral ulceration, subcutaneous nodules, alopecia). The ANA test was positive in all patients.
CONCLUSION: Long-term exposure to minocycline may be associated with drug-induced lupus. Baseline and periodic liver function and ANA tests accompanied by appropriate clinical monitoring are suggested for patients receiving long-term minocycline therapy. Copyright 2000 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10828631     DOI: 10.1159/000018387

Source DB:  PubMed          Journal:  Dermatology        ISSN: 1018-8665            Impact factor:   5.366


  18 in total

Review 1.  Drug-induced lupus erythematosus: incidence, management and prevention.

Authors:  Christopher Chang; M Eric Gershwin
Journal:  Drug Saf       Date:  2011-05-01       Impact factor: 5.606

Review 2.  Acne vulgaris.

Authors:  Guy F Webster
Journal:  BMJ       Date:  2002-08-31

3.  Minocycline suppresses activation of nuclear factor of activated T cells 1 (NFAT1) in human CD4+ T cells.

Authors:  Gregory L Szeto; Joel L Pomerantz; David R M Graham; Janice E Clements
Journal:  J Biol Chem       Date:  2011-01-31       Impact factor: 5.157

4.  Side effects of minocycline treatment in patients with fragile X syndrome and exploration of outcome measures.

Authors:  Agustini Utari; Weerasak Chonchaiya; Susan M Rivera; Andrea Schneider; Randi J Hagerman; Sultana M H Faradz; Iryna M Ethell; Danh V Nguyen
Journal:  Am J Intellect Dev Disabil       Date:  2010-09

Review 5.  Pharmacological regulators of autophagy and their link with modulators of lupus disease.

Authors:  Frédéric Gros; Sylviane Muller
Journal:  Br J Pharmacol       Date:  2014-09-05       Impact factor: 8.739

Review 6.  Minocycline for acne vulgaris: efficacy and safety.

Authors:  Sarah E Garner; Anne Eady; Cathy Bennett; John Norman Newton; Karen Thomas; Catalin Mihai Popescu
Journal:  Cochrane Database Syst Rev       Date:  2012-08-15

7.  Do selected drugs increase the risk of lupus? A matched case-control study.

Authors:  W Marieke Schoonen; Sara L Thomas; Emily C Somers; Liam Smeeth; Joseph Kim; Stephen Evans; Andrew J Hall
Journal:  Br J Clin Pharmacol       Date:  2010-10       Impact factor: 4.335

Review 8.  Drug-induced glomerular disease: immune-mediated injury.

Authors:  Jonathan J Hogan; Glen S Markowitz; Jai Radhakrishnan
Journal:  Clin J Am Soc Nephrol       Date:  2015-06-19       Impact factor: 8.237

9.  Trends in Oral Antibiotic Prescription in Dermatology, 2008 to 2016.

Authors:  John S Barbieri; Ketaki Bhate; Kathleen P Hartnett; Katherine E Fleming-Dutra; David J Margolis
Journal:  JAMA Dermatol       Date:  2019-03-01       Impact factor: 10.282

10.  Comprehensive behavioral testing in the R6/2 mouse model of Huntington's disease shows no benefit from CoQ10 or minocycline.

Authors:  Liliana B Menalled; Monica Patry; Natalie Ragland; Phillip A S Lowden; Jennifer Goodman; Jennie Minnich; Benjamin Zahasky; Larry Park; Janet Leeds; David Howland; Ethan Signer; Allan J Tobin; Daniela Brunner
Journal:  PLoS One       Date:  2010-03-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.